Is Scribe Therapeutics Inc. (SCTX) a Buy, Sell, or Hold?
NASDAQ : SCTX
Scribe Therapeutics Inc. — News
$24.93 USD
-$1.07 (-4.12%)
- Volume
- 149.88K
- Average Volume
- 270.33K
- Market Capitalization
- $403.42M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $26.50
- Year Low
- $17.31
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
| Source | Headline |
|---|---|
|
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the closing of its upsized initial public offering of 9,867,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,287,000 additional shares, at the initial public offering price of $15.00 per share. globenewswire.com - 2026-07-27 16:05:00 |
|
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized initial public offering of 8,580,000 shares of its common stock at the high end of the range at a public offering price of $15.00 per share. globenewswire.com - 2026-07-23 21:08:00 |
